Prevalence of methotrexate intolerance in juvenile idiopathic arthritis and possible risk factors: a tertiary center experience

Abstract views: 69


  • Zahide Ekici Tekin Ankara City Hospital
  • Melike Mehveş Kaplan Ankara City Hospital
  • Merve Cansu Polat Ankara City Hospital
  • Elif Çelikel Ankara City Hospital
  • Vildan Güngörer Ankara City Hospital
  • Tuba Kurt Ankara City Hospital
  • Nilüfer Tekgöz Ankara City Hospital
  • Müge Sezer Ankara City Hospital
  • Cüneyt Karagöl Ankara City Hospital
  • Serkan Coşkun Ankara City Hospital
  • Nimet Öner Ankara City Hospital
  • Banu Çelikel Acae Ankara City Hospital



juvenile idiopathic arthritis, methotrexate, intolerance, nausea


Methotrexate that has a safe and inexpensive profile is a first choice of juvenile idiopathic arthritis treatment. Nevertheless, gastrointestinal symptoms are not serious but common side effects of methotrexate. Sometimes patients may have nausea by thinking methotrexate and even refuse methotrexate use. In this study, we aimed to define prevalence of methotrexate side effects in juvenile idiopathic arthritis and the possible risk factors for methotrexate intolerance. Methotrexate intolerance severity score showed severity of gastrointestinal symptoms. Eighty-seven patients accepted to join study and answered the questions. The prevalence of adverse events of methotrexate was 64.4% and the rate of gastrointestinal symptoms was 55.2%. The nausea (27.6%) was the most common gastrointestinal symptom. The median of methotrexate intolerance severity score was 14.5 (interquartile range: 10-18). However, there was no significant difference in main parameters between tolerant and intolerant groups and no risk factor was observed for methotrexate intolerance. As a conclusion, methotrexate is an important actor for juvenile idiopathic arthritis treatment as a first and safe drug and, prospective studies in larger cohorts is necessary to understand and prevent occurrence of gastrointestinal symptoms.

Distribution of MTX intolerance at disease onset



How to Cite

Ekici Tekin, Z., Kaplan, M. M., Polat, M. C., Çelikel, E., Güngörer, V., Kurt, T., Tekgöz, N., Sezer, M., Karagöl, C., Coşkun, S., Öner, N., & Çelikel Acae, B. (2022). Prevalence of methotrexate intolerance in juvenile idiopathic arthritis and possible risk factors: a tertiary center experience. The Journal of Pediatric Academy, 3(2), 60–64.